Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.66 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.65 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.64 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.62 |
| ▸ | STS | P08842 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | PLD2 | O14939 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4651812 | 0.97 | ESR1 (0.71) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL4651711 | 0.96 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| Hydrochloric Acid SCHEMBL7946095 | 0.95 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL4653095 | 0.94 | ESR1 (0.70) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL8442470 | 0.94 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL4653105 | 0.94 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL8042270 | 0.94 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL4651801 | 0.93 | ESR1 (0.75) | ESR1ESR2ABCC1STSMEN1 | |
| Hydrochloric Acid SCHEMBL7946173 | 0.92 | ESR1 (0.74) | ESR1ESR2ABCC1STSMEN1 | |
| SCHEMBL8437216 | 0.92 | ENPP3 (0.72) | ESR1ESR2ENPP3ENPP1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6124311-A | ADMINISTERING ONCOLYTIC AGENT WITH ENHANCED MULTIDRUG RESISTANCE REVERSING AMOUNT OF SPECIFIED COMPOUND | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| US-6121292-A | BY ADMINSTERING A SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE, INDOLE, OR (DIHYDRO)NAPHTHYLENE, OF GIVEN FORMULA SUCH AS (6-(N-BUTYLSULFONOYL)-2-(4(N-BUTYLSULFONYL)PHENYL)BENZO(B)-THIEN-3-YL)(4(2 -(1-PIPERIDINYL)ETHOXY)PHENYL)METHANONE | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | claimed |
| EP-0735821-A4 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | LILLY CO ELI (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0735821-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | claimed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| EP-1093803-B1 | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | SANOFI AVENTIS (FR) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077333-A2 | USE OF A NEUROPEPTIDE Y ANTAGONIST FOR DAMAGED OR SENSITIVE LIPS | L'OREAL (FR) | 2007-07-12 | — | — | WO | disclosed |
| EP-0838217-B1 | Cosmetic composition containing neuropeptide Y receptor antagonist | SANOFI SYNTHELABO (FR) | 2003-01-15 | — | — | EP | disclosed |
| US-6313128-B1 | CAN BE USED AS LYPOLYSIS/LYPOGENESIS REGULATORS IN THE SKIN WITHOUT, INTERFERRING WITH THE SKIN'S NATURAL FUNCTIONS; FOR THERAPY OF SABORRHEA AND ACNE | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1132463-A2 | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | SANOFI-SYNTHELABO (FR) | 2001-09-12 | — | — | EP | disclosed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5482949-A | INHIBITING BONE LOSS, LOWERING CHOLESTEROL LEVELS, AND TREATING ESTROGEN DEPENDENT MAMMARY OR UTERINE CARCINOMA | ELI LILLY AND COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| WO-1995017382-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| EP-0617030-A1 | Sulfonate and carbamate derivatives of 3-aroylbenzo (beta) thiophenes | ELI LILLY AND COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |